Profile: Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

72.19USD
2:14pm EDT
Price Change (% chg)

$3.94 (+5.77%)
Prev Close
$68.25
Open
$71.92
Day's High
$73.84
Day's Low
$70.62
Volume
88,651
Avg. Vol
147,315
52-wk High
$73.84
52-wk Low
$15.77

Search Stocks

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (IEMs) are treated. The Company has identified and validated novel and druggable targets in both cancer and IEMs. The Company’s two advanced cancer programs are targeting mutations in the enzymes isocitrate dehydrogenase 1 and 2, referred to as IDH1 and IDH2. The Company’s drug candidates are selective for the mutated forms of IDH1 and IDH2 found in cancer cells versus the normal forms of IDH1 and IDH2 found in all other cells.

The Company focused on developing medicines to address IEMs, with a novel approach to these orphan diseases for which no effective or disease-modifying therapy is available. The Company has also de-validated and terminated numerous programs, including many that have been reported in scientific journals. In the Company’s IEM portfolio, it uses an equally rigorous set of validation techniques.

Company Address

Agios Pharmaceuticals Inc

2nd Floor,
38 Sidney Street
CAMBRIDGE   MA   02139-4169
P: +1617.6498600
F: +1302.6555049

Search Stocks